AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05757596
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Saline, volume matched
Trial: NCT05931484
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of Placebo
Trial: NCT05504265
Drug: Preemptive flurbiprofen axetil
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg once，30min before induction anesthesia
Trial: NCT05504265
Drug: Postoperative flurbiprofen axetil
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg bid
Trial: NCT06492512
Drug: daily ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill daily
Trial: NCT06492512
Drug: alternate day ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill every other day
Trial: NCT04049331
Drug: Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: first two doses four weeks apart; following three more doses every ten weeks.
Trial: NCT05910827
Drug: HMBD-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMBD-001 is a humanized Immunoglobulin G1 (IgG1) anti-Human Epidermal Growth Factor Receptor 3(HER3) monoclonal antibody (mAb). It is administered intravenously (IV) weekly
Trial: NCT06045936
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline injection
Trial: NCT04806451
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-active dosage form
Trial: NCT04822961
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Senaparib-matched placebo capsules
Trial: NCT05876598
Drug: antibiotic treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The outcome of the study will be to implement Prediction Models to support clinicians for the assessment of risk of having a bloodstream infection.
Trial: NCT05303090
Drug: H101
RxNorm normalized name: Avicel PH101 (Microcrystalline Cellulose NF) for Compounding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H101 intratumorally injection starts at day 0.
Trial: NCT06242028
Drug: Group P
RxNorm normalized name: High mobility group protein HMGI-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this group, US guided PENG block will be performed with 20 cc 0.25% bupivacaine and 4 mg dexamethasone.
Trial: NCT06242028
Drug: Group S
RxNorm normalized name: Blood group substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this group, US guided PENG block will be performed with 20 cc 0.25% bupivacaine. In addition, 4 mg dexamethasone will be administered intravenously.
Trial: NCT06800612
Drug: Oncologic drug administered for treatment of gynecologic cancer
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Data on oncologic drugs administered for treatment of gynecologic cancer will be recorded
Trial: NCT05664477
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo product with identical shape, size and color will be produced with absence of S-equol, daidzein and genistein. Ingredients include calcium carbonate, comprecel M102, croscarmellose sodium, stearic acid, Zeofree 5162, magnesium stearate, carnauba wax, coating cellulose clear (PEG), coating white (PEG), water.
Trial: NCT05620771
Drug: Y90 + TKI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive TKI for 21 days after standard of care therapy is complete.
Trial: NCT04782960
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 saline
Trial: NCT06424665
Drug: FZ-AD005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every 21 days for 1 cycle. Subjects will receive an intravenous infusion of FZ-AD005 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
Trial: NCT06162221
Drug: RMC-6291
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT06162221
Drug: RMC-9805
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT05505916
Drug: KVD900 600 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KVD900 Tablet 600 mg (2 x 300 mg)
Trial: NCT04652726
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile normal saline (0.9% sodium chloride in water for subcutaneous injection)
Trial: NCT04541147
Drug: Analgesics
RxNorm normalized name: ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standardization of post-operative analgesics (narcotics and non-narcotic medication).~* Oxycodone solution or tablet (depending on age of patient) at 0.05-0.1 mg/kg/dose every 6hrs; max 5mg (obese/OSA); prescribe 30 doses~* Acetaminophen 10-15 mg/kg/dose every 6 hours; max 500mg per dose; prescribe 56 doses (over the counter medication)~* Ibuprofen 5-10 mg/kg/dose every 6 hours; max 200 mg/dose; prescribe 56 doses (over the counter medication)
Trial: NCT06286397
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of a vehicle cream to the natal cleft twice daily for 12 weeks
Trial: NCT06204094
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2, PO, BID, d1-14 of each cycle\*8cycles
Trial: NCT05750680
Drug: DOACs
RxNorm normalized name: Doans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: outpatients visited in anticoagulation clinics with a prescription of DOAC for atrial fibrillation and venous thromboembolism and concomitant antiepileptic drug will perform a blood draw for measurement of dabigatran, rivaroxaban, apixaban and edoxaban
Trial: NCT04711863
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 200 mg per day as tolerated until discharge from community treatment center or for approximately 10 days
Trial: NCT06240455
Drug: WP1302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
Trial: NCT06240455
Drug: WP1302 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
Trial: NCT06332430
Drug: CAN2109
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAN2109 IT injection (once every 3 weeks)
Trial: NCT05695664
Drug: Ibuprofen 800 mg
RxNorm normalized name: ibuprofen 800 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous injection of ibuprofen 800 mg
Trial: NCT05695664
Drug: Ketorolac Injection
RxNorm normalized name: ketorolac Injection
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous injection of Ketorolac 30 mg
Trial: NCT04288115
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will be instructed to start the study medication the day after randomization. The study medication will be taken orally once a day.
Trial: NCT04724447
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo equivalent of 900mg/day VGCV
Trial: NCT06561698
Drug: Minocycline,Metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics for H. pylori eradication
Trial: NCT05549778
Drug: Polaprezinc group
RxNorm normalized name: polaprezinc
DrugBank: Polaprezinc (DB09221)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abiraterone plus Polaprezinc for 6 months
Trial: NCT05549778
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abiraterone, radio- or chemotherapy
Trial: NCT05567458
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06421818
Drug: Baitouweng Tang
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baitouweng Decoction is composed of four herbs: Baitouweng, Rhizoma coptidis, Phellodendri huangbai and Qin Pi.
Trial: NCT06300411
Drug: SRG-514
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRG-514 monotherapy
Trial: NCT06475846
Drug: HRS5580
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS5580; low dose
Trial: NCT06475846
Drug: HRS5580
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS5580; middle dose
Trial: NCT04985942
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching capsules administered orally, once daily.
Trial: NCT05351398
Drug: Traditional group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. In this group, patients are treated with the SOX regimen.
Trial: NCT06205420
Drug: Injectable giomer restoration
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The teeth affected with enamel hypoplasia will be prepared by removing all defective enamel to place the restorations on sound tooth structure as recommended by the IAPD.~A tooth-by-tooth approach will be employed, where adjacent teeth will be isolated with Teflon tape before selective enamel etching. Selective etching of cut enamel will be done for 15 seconds using 37% phosphoric acid gel. Self-etch adhesive system will be used and an injectable giomer restoration will be injected in the accurately positioned transparent clear stent through the small channels created by the tip of the restoration syringe in the incisal edge to restore the affected teeth.~Curing will be done on the incisal and labial aspects for 20 seconds and will be repeated after clear stent removal for additional 20 seconds. After removal of the clear stent from the patient's mouth, the restoration sprue as well as excess polymerized restoration will be scrapped off with a scalpel.
Trial: NCT05861440
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: adjunct steroid per study protocol
Trial: NCT05861440
Drug: standard anti-tuberculosis agents
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard anti-tuberculosis agents
Trial: NCT06635538
Drug: Clomiphene Citrate (CC) 100 mg/day from D1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On day 2 or 3 of the menstrual cycle or after 5 days of pill-free interval, the patients will start oral administration of Clomiphene Citrate 100/day continuing up to and including the day of ovulation triggering
Trial: NCT06635226
Drug: ID110521156
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ID110521156 capsules taken orally once daily
Trial: NCT06635226
Drug: Placebo of 110521156
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ID110521156 placebo capsules taken orally once daily
Trial: NCT04955470
Drug: Normal Saline 0.9% Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 0.9% normal saline solution will be infused over a 40 minute period.
Trial: NCT05882292
Drug: ABN401
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABN401 800 mg will be administered orally once daily immediately after a meal \[should be within 1 hour post-meal (fed state)\] at approximately the same time each day in a 21-day cycle.
Trial: NCT06451159
Drug: Chemotherapy: cyclophosphamide (CYC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive one 3-day cycle of lymphodepletion with CYC 300 mg/m2 prior to administration of KYV-101.
Trial: NCT05364515
Drug: PRGF
RxNorm normalized name: Platelet-Rich Growth Factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma Rich in Growth Factors (PRGF) is a mixture of proteins and growth factors obtained from the blood of the patient.~Four PRGF infiltrations (two weeks between each infiltration). Then, application of topical PRGF serum (on alternate basis)
Trial: NCT05961644
Drug: 0.9% Chloride Injection Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride injected subcutaneously, 10 ml daily, for 2-3 consecutive days
Trial: NCT06132828
Drug: DR30206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive DR30206 intravenously
Trial: NCT06630806
Drug: SAR446523
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Powder for solution for injection; Route of administration: Subcutaneous (SC)
Trial: NCT06629597
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered orally at 1000 mg/m2 twice a day (BID) on Days 1 to 14 of each 3-week cycle
Trial: NCT06365437
Drug: Corticosteroids (CS)
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care Concomitant Immunosuppression
Trial: NCT06336161
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: to compare between Ultrasound-Guided ESPB and Ultrasound-Guided CEI for postoperative pain relief in patients who underwent lumbosacral surgeries.
Trial: NCT05650528
Drug: QG101-23-0 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single and Multiple Dose for oral
Trial: NCT05650528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single and Multiple Dose for oral
Trial: NCT05213507
Drug: aerosol inhaled Amikacin Sulfate Injection
RxNorm normalized name: amikacin Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4g Amikacin sulfate injection + 5ml saline, aerosol inhalation, b.i.d., 7-10 days per month, for 3 months.
Trial: NCT05049733
Drug: CBD 1mg/Kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will ingest soft gel tablets containing CBD 1mg/Kg
Trial: NCT05049733
Drug: CBD 2mg/Kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will ingest soft gel tablets containing CBD 2mg/Kg
Trial: NCT05049733
Drug: CBD 4mg/Kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will ingest soft gel tablets containing CBD 4mg/Kg
Trial: NCT05049733
Drug: Placebo CBD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will ingest soft gel tablets containing placebo for CBD
Trial: NCT06148389
Drug: STSA-1301 subcutaneous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive the administration dose on Day 0 following protocol requirements.
Trial: NCT06148389
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive the administration dose on Day 0 following protocol requirements.
Trial: NCT04767217
Drug: artemether-lumefantrine (ALN)
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessing the efficacy on current 1st line antimalarial, and an alternative 1st line or 2nd line medicine
Trial: NCT05680740
Drug: VTAMA® (tapinarof) Cream 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VTAMA® (tapinarof) Cream 1% applied topically once daily
Trial: NCT05896228
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Acetaminophen orally (PO) prior to Iber-KDd therapy as follows:~* Cycles 1 and 2: 650 mg/dose on Days 1, 8, 15, and 22~* Cycles 3 through 6: 650 mg/dose on Days 1 and 15~* Cycles 7 and 8: 650 mg/dose on Day 1.
Trial: NCT04973189
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of matching SHR-1707 placebo by intravenous (IV) infusion in healthy young adults.
Trial: NCT04973189
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of matching SHR-1707 placebo by intravenous (IV) infusion in elderly subjects.
Trial: NCT05275660
Drug: HFB30132A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to HFB30132A will be administered dose 1 in cohort 1. Participants in Cohort 2 will receive HFB30132A dose 2.
Trial: NCT06801522
Drug: Adrenaline nasal pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline is direct acting, non selective, adrenergic agonist binding with alpha and beta receptors both, used for vasoconstriction to decrease nasal bleeding.
Trial: NCT05481879
Drug: DYNE-101
RxNorm normalized name: Barrier-Dyne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by IV infusion
Trial: NCT05481879
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by IV infusion
Trial: NCT06400771
Drug: DNP007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNP007 is a therapeutic agent that can replace calcineurin inhibitor (CNI), which is a representative factor that can be used as an adhesive for extrahepatic long-term survival patches such as after liver transplantation in patients with liver disease and hepatocellular carcinoma, adult metabolic status, neoplasms, etc. , an anti-ICAM-1 mouse monoclonal minority, is a humanized Fab region that humanizes MD-3 and the Fc region of human IgG1, separated by translational engineering.
Trial: NCT06518694
Drug: Βeta-Blockers discontinued (with tapering)
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The experimental group will undergo discontinuation of their beta-blockers treatment during the study period.~The tapering of beta-blocker will start on the day after randomisation and is based on a reduction by half-dose every 48 hours (1/2 maximally recommended dose for 48 hours, then ¼ maximally recommended dose for 48 hours) until reaching the minimal recommended dosage (1/8 maximally recommended dose) for 48 hours before complete interruption of treatment. Consequently, the tapering will not be needed in patients already receiving the minimal recommended dosage (i.e., 1/8 dose) at inclusion, and these patients will be instructed to stop taking beta-blockers the day after randomisation.
Trial: NCT06226662
Drug: NM8074
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NM8074 will be administered as an intravenous infusion. In Cohort 1, all subjects will be administered 20 mg/kg of NM8074 intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period.
Trial: NCT06226662
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline Placebo will be administered as an intravenous infusion. In Cohort 2, all subjects will be administered saline placebo intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period.
Trial: NCT06453551
Drug: TRN501 - Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
Trial: NCT06453551
Drug: TRN501 - Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
Trial: NCT06453551
Drug: TRN501 - Dose 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
Trial: NCT06453551
Drug: TRN501 - Dose 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
Trial: NCT05660473
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alkylating agent
Trial: NCT05660473
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Antifolate antineoplastic drug
Trial: NCT06016972
Drug: Experimental: QLS-111 ophthalmic solution, (0.03%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QLS-111 ophthalmic solution, (0.03%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
Trial: NCT06016972
Drug: Experimental: QLS-111 ophthalmic solution, (0.075%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QLS-111 ophthalmic solution, (0.075%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.